Chimeric Therapeutics shows promise in ovarian and pancreatic cancers

Chimeric Therapeutics (ASX:CHM), an Australian company specialising in cell therapy, has reported significant in vitro findings for its chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell therapy, CHM 1301. These preclinical results highlight the therapy's notable efficacy against ovarian and pancreatic cancers, suggesting potential advancements in cancer treatment.

Read More